INVEST IN THE FUTURE OF PAIN RELIEF
Pain is universal. It disrupts work, time with family, and quality of life. Through innovations, we can make a difference.
VIRPAX Pharmaceuticals is collaborating with the best minds of the pharmaceutical industry. Working alongside these leaders, we can improve pain management and target pain at its source.
Partner with us as we develop the next generation of pharmaceutical products that can minimize pain and improve people’s lives.
BECOME A PARTNER
484.880.4588 info@virpaxpharma.com
Virpax’s MMS019 Inhibits SARS-COV-2 in Ex-Vivo Airway Model
Virpax® Pharmaceuticals Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management, today announced that based on recent ex-vivo studies, MMS019, a high-density mucoadhesive polymer, has demonstrated reduction of infectivity from respiratory viruses like influenza and SARS-COV-2. MMS019 contains a positively charged polymer that has been through [...]
Chester County drug developer Virpax working on ‘molecular mask’ to combat Covid-19
By John George – Senior Reporter, Philadelphia Business Journal Virpax Pharmaceuticals Inc. has joined the battle against Covid-19 through a new technology licensing agreement with a London life sciences company. The Chester County drug developer signed the deal with Nanomerics Ltd. for the exclusive North America rights to [...]
Virpax Enters into an NIH Collaboration to Further Develop NES100 for Acute and Chronic Non-Cancer Pain
Announces CRADA with National Center for Advancing Translational Sciences Virpax Pharmaceuticals, Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management, today announced that it has entered into a cooperative research and development agreement with the National Center for Advancing Translational Sciences (NCATS), an institute/center of the [...]